Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus

This study has been completed.

Sponsor:

Information provided by:

Novartis

ClinicalTrials.gov Identifier:

NCT00136773

First received: August 25, 2005

Last updated: March 8, 2011

Last verified: March 2008

History of Changes

Purpose

Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.

Condition	Intervention	Phase
Albuminuria	Drug: amlodipine/benazepril	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment
Official Title:	Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:

Drug Information available for: Benazepril hydrochloride Benazepril Amlodipine Amlodipine besylate Lotrel

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Change from baseline in the urine albumin/creatinine ratio after 52 weeks

Secondary Outcome Measures:

Percentage of patients who have progressed to diabetic kidney disease (urine albumin/creatinine ratio ≥ 300 µg/mg creatinine) after 52 weeks
Change from baseline in the ratio of urine albumin/creatinine ratio an estimate of kidney function after 52 weeks
Change from baseline in insulin resistance after 52 weeks
Change from baseline in urine albumin secretion after 52 weeks
Change from baseline in a marker of heart failure after 52 weeks


Enrollment:	332
Study Start Date:	April 2003
Study Completion Date:	November 2005
Primary Completion Date:	October 2005 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	21 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:	All

Criteria

Inclusion Criteria:

Mild to moderate hypertension
Type 2 diabetes mellitus
Presence of protein in the urine (albuminuria)

Exclusion Criteria:

Kidney disease not caused by diabetes or hypertension
Renal artery stenosis
Myocardial infarction or stroke within the last 6 months
Type 1 diabetes mellitus
Pregnant or lactating females
Cancer within the last 5 years

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00136773

Sponsors and Collaborators

Novartis

Investigators


Study Director:	Novartis Pharmaceuticals	Novartis Pharmaceuticals

More Information


ClinicalTrials.gov Identifier:	NCT00136773 History of Changes
Other Study ID Numbers:	CCIB002FUS12
Study First Received:	August 25, 2005
Last Updated:	March 8, 2011

Keywords provided by Novartis:


Albuminuria Type 2 diabetes mellitus Hypertension

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 2 Albuminuria Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Proteinuria Urination Disorders Urologic Diseases Urological Manifestations Signs and Symptoms	Benazepril Amlodipine Antihypertensive Agents Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Vasodilator Agents Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors Enzyme Inhibitors

ClinicalTrials.gov processed this record on September 21, 2017

To Top